Grifols to Acquire Talecris Biotherapeutics Creating A World Leading Provider Of
Life-Saving Plasma Protein Therapies
The combination of Grifols and Talecris will create a diversified, global provider of life-saving and life enhancing plasma protein therapeutics built on the strong global presence of Grifols and the established position of Talecris in United States and Canada.
Read the full article »

Rotavirus Vaccine Is Now Contraindicated for Infants Diagnosed With Severe Combined Immunodeficiency
In response to reported cases of vaccine-acquired rotavirus infection in infants with severe combined immunodeficiency (SCID) following rotavirus vaccine administration, both Merck & Co. and GlaxoSmithKline Biologicals have revised the prescribing information and patient labeling for their respective rotavirus vaccine products, pentavalent rotavirus vaccine (RV5) and monovalent rotavirus vaccine (RV1), with approval from the Food and Drug Administration (1,2).
Read the full article »